Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!
top of page
Search
Recent Posts
See AllThe ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....
00
The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...
390
ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on...
190
+1 514-934-1934
1001 Decarie Blvd, Montreal, Quebec H4A 3J1, Canada
bottom of page
Comments